Riot Platforms, Inc. — Call Transcript 2014

Aug 11, 2014

8-K 1 appy_8k.htm FORM 8-K Licensed to: ETBS Document created using Disclosure Solutions PROFILE 2.6.0.0 Copyright 1995 - 2014 Thomson Reuters Accelus. All rights reserved.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) August 11, 2014

Venaxis, Inc.
(Exact name of Registrant as specified in its charter)

Colorado	001-33675	84-1553387
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

1585 South Perry Street Castle Rock, Colorado	80104
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (303) 794-2000

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Anchor o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On August 11, 2014, Venaxis, Inc. (the "Company") issued a press release titled — "Venaxis to Provide Second Quarter 2014 Update Including Ongoing FDA Process." The press release is filed as Exhibit 99.1 to this Form 8-K.

On August 11, 2014, the Company hosted an investor update call. The script for this investor call is filed as Exhibit 99.2 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibits

99.1	Press Release of Venaxis, Inc. titled "Venaxis to Provide Second Quarter 2014 Update Including Ongoing FDA Process," issued August 11, 2014.
99.2	Investor update conference call script dated August 11, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Jeffrey G. McGonegal
Name:	Jeffrey G. McGonegal
Title:	Chief Financial Officer